PBYI
Strong BuyFull HouseAI neutralPuma Biotechnology, Inc. · Healthcare · United States · $479M cap · $3.3M/day traded
$10.12 -1.7% · close 13 Oct · scored 14 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
As of 14 Oct 2026, MoatMap's StockRank for Puma Biotechnology, Inc. (PBYI) is 98/100, ranked against 24,000+ stocks in 35 markets (Quality 85, Value 57, Momentum 69, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Puma Biotechnology demonstrates high operational quality driven by commercialization of Nerlynx, but its valuation remains constrained. Recent regulatory filings indicate net share disposals by corporate officers, while overall valuation support remains mixed. Absent clear management buying or upgraded earnings momentum, evidence does not point to a clear inflection.
ABOUT PUMA BIOTECHNOLOGY, INC.
Read
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of cancer. Its lead product, Nerlynx, is approved for certain types of early-stage HER2-positive breast cancer. The company's competitive position is anchored by its approved oncology therapeutic and ongoing clinical development pipeline, operating in the high-stakes pharmaceutical market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 228.0M | 235.6M | 230.5M | 228.4M | 0.0% | 231.2M |
| EPS | 0.00 | 0.46 | 0.62 | 0.62 | 16.1% | 0.51 |
| Shares | 46.3M | 47.6M | 49.1M | 50.4M | +8.8% | 51.6M |
| Debt | 114.3M | 111.5M | 74.1M | 28.5M | -37.0% | 4.8M |
| Equity | 21.6M | 53.4M | 92.1M | 130.3M | 82.0% | — |
| Op CF | -15.8M | 27.0M | 38.9M | 41.8M | 24.4% | 41.1M |
| Inv CF | 7.1M | -19.1M | -20.4M | -36.2M | — | — |
| Fin CF | 12.2M | 0 | -33.8M | -45.2M | — | — |
Above its 200-day average and 2% below its 52-week high.
Swung more than 74% of stocks we rank over the past year (59% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBYI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PBYI | Puma Biotechnology, Inc.(you) | $479M | 98 | Strong Buy |
| CRMD | CorMedix Inc. | $599M | 98 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $672M | 92 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $280M | 95 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $226M | 99 | Strong Buy |
| QTTB | Q32 Bio Inc. | $285M | 88 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $696M | 74 | Buy |
| ABUS | Arbutus Biopharma Corporation | $961M | 81 | Strong Buy |
Peer medians: ROE -26.1% · P/E 29.0x · Gross margin 64.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.